Analysts Set Precigen, Inc. (NASDAQ:PGEN) PT at $7.00

Precigen, Inc. (NASDAQ:PGEN) has received an average recommendation of “Moderate Buy” from the five brokerages that are covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation and four have issued a buy recommendation on the company. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $7.00.

A number of brokerages have issued reports on PGEN. HC Wainwright restated a “buy” rating and set a $6.00 price objective (up from $4.00) on shares of Precigen in a research report on Thursday, January 23rd. JMP Securities restated a “market outperform” rating and set a $5.00 price objective on shares of Precigen in a research report on Tuesday, January 14th.

Institutional Investors Weigh In On Precigen

Several hedge funds and other institutional investors have recently added to or reduced their stakes in PGEN. Iridian Asset Management LLC CT grew its position in Precigen by 38.8% during the 4th quarter. Iridian Asset Management LLC CT now owns 5,241,922 shares of the biotechnology company’s stock worth $5,871,000 after purchasing an additional 1,465,962 shares during the period. LexAurum Advisors LLC grew its position in Precigen by 151.9% during the 4th quarter. LexAurum Advisors LLC now owns 691,544 shares of the biotechnology company’s stock worth $775,000 after purchasing an additional 417,055 shares during the period. Geode Capital Management LLC grew its position in shares of Precigen by 4.8% during the 3rd quarter. Geode Capital Management LLC now owns 3,246,508 shares of the biotechnology company’s stock valued at $3,075,000 after acquiring an additional 149,829 shares during the period. Charles Schwab Investment Management Inc. grew its position in shares of Precigen by 11.6% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,222,850 shares of the biotechnology company’s stock valued at $1,158,000 after acquiring an additional 127,467 shares during the period. Finally, HighTower Advisors LLC grew its position in shares of Precigen by 186.8% during the 3rd quarter. HighTower Advisors LLC now owns 192,144 shares of the biotechnology company’s stock valued at $179,000 after acquiring an additional 125,145 shares during the period. 33.51% of the stock is owned by institutional investors and hedge funds.

Precigen Trading Up 3.4 %

NASDAQ:PGEN opened at $1.80 on Tuesday. The company has a market capitalization of $527.16 million, a P/E ratio of -3.27 and a beta of 1.57. Precigen has a 12 month low of $0.65 and a 12 month high of $2.17. The business’s 50-day moving average is $1.55 and its 200 day moving average is $1.13.

About Precigen

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.